Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Artificial Intelligence in Gynecologic Imaging
Briggs, Morgan, Saif, Ayesha, Kline, Timothy L. , VanBuren, Wendaline, Green, Isabel C. , L Kline, Timothy, Briggs, Morgan , VanBuren, Wendaline M. , Rassier, Sarah L. Cohen

Mayo Clinic

Clinical Obstetrics & Gynecology | January 23, 2026 | Volume: 69 | Issue: 1 | Pages: 26-35

10.1097/grf.0000000000000984 | PMID 41576324 Get It

What was done? A review of artificial intelligence (AI) applications for the imaging of uterine fibroids, endometriosis, and adenomyosis. What was found? AI models can assist with the recognition, segmentation, and localization of uterine fibroids, and the differentiation of benign fibroids and sarcomas. Models can aid in the diagnosis of adenomyosis and endometriosis, and the prediction of the impact of endometriosis on fertility. What the findings mean? Deployed thoughtfully, AI tools could reduce variability, shorten read times, and add objective measurements to routine care. Studies evaluating these models are limited by single-institution designs and continued reliance on expert sonologists and radiologists.
The Feasibility and Preliminary Effectiveness of a 6-Week Independent Cadence Retraining Program on Parous Runners With Stress Urinary Incontinence
Ron, Nicole J., Olmstead, Sally R., Collum, Layne K., Conway, Sarah A., Hayes, Elyse, Kolacz, Abigail L., Hollman, John H.

Mayo Clinic

Journal of Women's & Pelvic Health Physical Therapy | January 23, 2026 | Volume: 50 | Issue: 1 | Pages: 34-41

10.1097/jwh.0000000000000359 Get It

Background: Running often elicits stress urinary incontinence (SUI) in parous athletes. While cadence retraining improves running biomechanics, its impact on incontinence is unclear. This feasibility study assessed the implementation and preliminary effects of a 6-week cadence retraining program in parous female runners with SUI. Methods: A total of 8 participants with self-reported SUI and a preferred running cadence ≤ 170 steps/minute underwent treadmill testing before and after the intervention. The program involved a 6-week cadence retraining program using a Garmin Forerunner 55 watch. Feasibility was assessed across 6 domains. Running outcome measures included cadence and vertical oscillation. SUI outcome measures included the Questionnaire for Urinary Incontinence Diagnosis and Urinary Distress Inventory-6 scores. Paired t-tests were conducted (α = .05). Results: Following the 6-week program, feasibility outcomes supported the viability of study procedures and high adherence. Statistically significant increases in cadence ( P = .016) and decreases in vertical oscillation ( P = .019) and concomitant decreases in Questionnaire for Urinary Incontinence Diagnosis ( P = .013) and Urinary Distress Inventory-6 ( P = .042) scores were observed. Discussion: This study demonstrated the feasibility and acceptability of a 6-week cadence retraining program for parous runners with SUI. Given the growing movement to foster athleticism after pregnancy, these findings will appeal to physical therapists searching for acceptable treatment options for SUI in parous runners. Preliminary running mechanics and SUI symptoms warrant a larger randomized controlled trial. A power analysis estimated a sample size of 66 participants for a future full-scale efficacy study.
Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study
Alsina, Melissa , Shah, Nina, Jagannath, Sundar, Kaufman, Jonathan L., Siegel, David, Munshi, Nikhil C., Rosenblatt, Jacalyn , Lin, Y, Jakubowiak, Andrzej , Li, Aojun, Mao, Pingping, Fincker, Maeva, Yeri, Ashish , Campbell, Timothy , Finney, Olivia , Truppel-Hartmann, Anna, Petrocca, Fabio , NS, Raje, Jagannath, Sundar , Kaufman, Jonathan L. , Lin, Yi , Siegel, David S. , Shah, Nina , Jagannath, Sundar , Kaufman, Jonathan L , Siegel, David , Munshi, Nikhil C , Lin, Yi , Jakubowiak, Andrzej , Derman, Benjamin A , Li, Aojun , Mao, Pingping , Fincker, Maeva , Yeri, Ashish , Martin, Nathan , Campbell, Timothy , Finney, Olivia , Truppel-Hartmann, Anna , Petrocca, Fabio , Berdeja, Jesús G , Raje, Noopur S , Munshi, Nikhil C. , Derman, Benjamin A. , Martin, Nathan , Berdeja, Jesús G.

Mayo Clinic

Cancer Immunology Research | January 21, 2026 | Volume: 14 | Issue: 4 | Pages: 528-542

10.1158/2326-6066.cir-24-0527 | PMID 41562447 Get It

Abstract Chimeric antigen receptor (CAR) T-cell therapy enriched for a memory-like phenotype may persist and function longer than a nonenriched product, thereby improving duration of response (DOR). We conducted a phase I study with bb21217 (NCT03274219), an anti–B-cell maturation antigen CAR T-cell therapy manufactured in the presence of the phosphoinositide 3-kinase inhibitor bb007 to enrich for T cells with a memory-like phenotype, in patients with relapsed/refractory multiple myeloma (N = 72). No new safety concerns were raised with bb21217 therapy (three cases each of grade ≥3 cytokine release syndrome and grade ≥3 neurotoxicity were observed). The objective response rate was 69.4% and the median DOR was 23.8 (95% confidence interval, 16.8–34.8) months. Analysis of the drug product established an association between early memory phenotype and robust expansion and depth of response. Examination of baseline characteristics indicated that tumor burden and prior therapies influenced DOR. The data indicate that generation of CAR T cells early in a disease course when tumor burden is lower and source material exhibits a more naïve phenotype may maximize the clinical benefit potential of the drug product.
Genetics and Brain Health in Adults With Congenital Heart Disease: A Consensus Statement From the ACHD/Neuro 2024 Conference
Field, Thalia S., Morton, Sarah U. , Brossard‐Racine, Marie , Cohen, Scott , Feldman, Howard , Chung, Ai Wern , Newburger, Jane W., Puder, Rick, Gurvitz, Michelle , Cassidy, Adam, Newburger, Jane W. , Field, Thalia S. , Field, Thalia S , Feldman, Howard H , Newburger, Jane W , Cassidy, Adam R , Cassidy, Adam R.

Mayo Clinic

Journal of the American Heart Association | January 19, 2026 | Volume: 15 | Issue: 2 | Pages: No page available

10.1161/jaha.125.042617 | PMID 41553060 Get It

With improvement in medical and surgical care, the number of adults with congenital heart disease (CHD) is soaring. Adults with CHD commonly have impairments in brain health. However, significant gaps in knowledge remain regarding the relevant types and prevalence of neurologic and psychiatric risk and their associated risk factors. We sought to review current evidence, identify gaps in knowledge, and develop key next steps to improve scientific understanding and clinical care. Three working groups—Genetics and Brain Health, Characterizing Neuropsychological and Psychological Outcomes, and Neuropsychological and Psychosocial Interventions—were composed of multidisciplinary experts in relevant clinical and research domains, as well as adults with CHD. Each group identified 5 key knowledge gaps and associated next investigations needed to address those gaps. For Genetics and Brain Health, 5 key knowledge gaps were identified: lack of a standardized neuroimaging protocol for adults with CHD, need to understand neuroradiological–pathological–neuropsychological correlates, role of gene–environment interactions, what can be learned from brain health risk models from other groups, and how existing multimodal approaches influence risk and neuroresilience. Adults with CHD can benefit from routine assessment of brain health, as well as increased clinical and basic research into the underlying factors that contribute to risk and neuroresilience for neurologic and psychiatric sequalae. Multidisciplinary collaborative efforts that incorporate adults with CHD across the research cycle are essential for all key next steps.
Exercise, nutrition, and psychological support for kidney cancer: a scoping review
Briggs, Logan , Gill, Vikram S., Ligten, Matthew J. Van, Beck, Kelsey L., Sinha, D.T. , Choudry, Mouneeb, Bain, Paul , Quillen, Jaxon , Abdul‐Muhsin, Haidar, Andrews, Paul E. , Briggs, Logan G , Van Ligten, Matthew J, Sinha, Debarshi, Dodoo, Christopher A, Abdul-Muhsin, Haidar M , Trinh, Quoc-Dien , Parke, Sara C. , Gill, Vikram S., Ligten, Matthew J. Van, Beck, Kelsey L., Alkhatib, Khalid Y. , Dodoo, Christopher , Pierorazio, Phillip , Trinh, Quoc‐Dien , Psutka, Sarah P.

Mayo Clinic

BJU International | January 19, 2026 | Volume: 137 | Issue: 4 | Pages: 579-595

10.1111/bju.70134 | PMID 41549535 Get It

Objectives To comprehensively review the available literature on prehabilitation and rehabilitation exercise, nutrition, and psychological support interventions for patients with kidney cancer (KC), to summarise the clinically relevant efficacy and cost‐effectiveness of interventions, to expose key knowledge gaps, and to inform future investigations and initiatives. Methods This review was performed according to the per Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) Extension for Scoping Reviews Guidelines. We included randomised controlled trials (RCTs) assessing programmes of prehabilitation or rehabilitation, exercise, psychological support, or nutrition components in patients with KC or KC caregivers from January 2004 to March 2022. Statistically significant positive (SS+) and negative (SS−) results were summarised. Results The systematic search yielded 10 968 records including 18 RCTs, involving 2774 unique subjects, 706 of whom were KC patients/survivors. None included caregivers or assessed cost‐effectiveness. Two interventions were implemented before surgery, one was implemented prior to initiation of systemic therapy, eight were implemented during systemic or radiation therapy, three were implemented after treatment, while implementation time was not specified for four interventions. Conclusion Most (14/18) RCTs involving exercise, nutrition, psychological support, or prehabilitative or rehabilitative programmes for KC performed to date demonstrated SS+ results. The evidence was most robust regarding previously evaluated psychological support, especially mindfulness‐based interventions (9/10 studies demonstrating SS+ improvement in primary outcomes), followed by therapeutically valid exercise with/without psychological support (5/8 RCTs demonstrated efficacy), then nutrition or pharmacological interventions (2/5 demonstrated efficacy). Level 1 evidence supports counselling patients and referral to mindfulness‐based psychological therapy along with physical therapy or physical medicine and rehabilitation, as well as consideration of preoperative carbohydrate drinks. No studies have examined impact on caregivers, or cost‐effectiveness, which are both critical areas for future study.
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET -Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Waliany, Sarah , Cooper, Alissa J. , Liu, Stephen V. , Gautschi, O., Rotow, Julia K. , Smith, Katherine E. , Weber, Urs, Lee, Dae Ho , Loong, H., Patel, Jyoti D. , Nagasaka, Misako , Patel, Shetal , Tan, Daniel S. W., Solomon, Benjamin J., Pall, Georg , Riess, Jonathan W. , Sun, Lova , Früh, Martin, Uy, Natalie F., Gadgeel, Shirish, Feng, Jamie, Leighl, Natasha B., Baik, Christina S. , Lai, G., Ou, S. Ignatius, Cheung, Kingsley S.Y., Patil, Tejas, Weiler, Daniela , Yeap, Beow Y., Wirth, Lori J. , Gainor, Justin F., Drilon, Alexander D., Lin, Jessica J., Loong, Herbert H. , Rotow, Julia , Gautschi, Oliver , Smith, Katherine E R , Weber, Urs M , Loong, Herbert H , Pennell, Nathan A , Nagasaka, Misako , Patel, Shetal A , Tan, Daniel S W , Solomon, Benjamin J , Kim, Tae Min , Pall, Georg , Riess, Jonathan W , Sun, Lova , Früh, Martin , Uy, Natalie F , Gadgeel, Shirish , Feng, Jamie , Do, Andrew , Falcon, Christina , Leighl, Natasha B , Baik, Christina S , Lai, Gillianne G Y , Ou, Sai-Hong I , Cheung, Kingsley S Y , Patil, Tejas , Mansfield, Aaron S , Weiler, Daniela , Yeap, Beow Y , Wirth, Lori J , Gainor, Justin F , Drilon, Alexander , Lin, Jessica J , Liu, Stephen V , Früh, Martin , Gadgeel, Shirish M. , Feng, Jamie , Mansfield, Aaron S. , Gainor, Justin F.

Mayo Clinic

Clinical Cancer Research | January 15, 2026 | Volume: 32 | Issue: 6 | Pages: 1157-1168

10.1158/1078-0432.ccr-25-4382 | PMID 41537704 Get It

Abstract Purpose: Rearranged during transfection (RET) alterations are oncogenic drivers across solid tumors. Selective RET inhibitors (SRI) selpercatinib and pralsetinib have transformed outcomes for patients with RET-altered malignancies. Limited knowledge exists on genomic mechanisms of resistance to SRI. Experimental Design: We established “RETgistry,” a global consortium of patients with advanced RET-altered solid tumors who received SRI and underwent postprogression tissue or plasma biopsies assessed by next-generation sequencing. Frequencies of secondary RET resistance mutations and acquired non-RET gene alterations were determined. Progression-free survival (PFS) and time to treatment discontinuation (TTD) on first SRI were estimated with the Kaplan–Meier method. Results: RETgistry included 109 patients with RET-altered advanced solid tumors (lung, n = 94; thyroid, n = 15) who underwent 143 post-SRI progression biopsies (tissue, 91; plasma, 52). The median PFS and TTD were 13.9 months [95% confidence interval (CI), 10.1–16.6] and 17.3 months (95% CI, 14–20.2), respectively. Secondary RET mutations were detected in 20 (14%) biopsies [lung cancer, 15 (12.4%) and thyroid carcinoma, 5 (22.7%)]. Common acquired off-target alterations involved MET (18.2%; amplification, 15%), TP53 (8.2%), APC (7.6%), KRAS (7.1%), KEAP1 (5.9%), and CDKN2A/B (5.3%). MET alterations were enriched in post-SRI versus pre-SRI specimens (full cohort, 17.6% vs. 2.0%, P = 0.022; lung cancer, 19.1% vs. 2.1%, P = 0.022). Conclusions: The prevalence of secondary RET mutations after SRI was low, underscoring a greater role for off-target resistance. Recurrent acquired alterations involving tumor suppressor genes or upstream regulators of MAPK and PI3K pathways were identified, most commonly MET amplification. Continued efforts to characterize SRI resistance biology are critical to guide the development of novel therapeutic strategies.
Prognostic role of PET / CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International
Gowdy, S. Claire , Flerlage, Jamie E. , Palese, Monica , Castellino, Sharon M., Cho, Steve , Dieckmann, Karin, Hoppe, Bradford S. , Howard, Scott, Kelly, Kara M., Kurch, Lars , Lai, Hollie , Lopci, Egesta, Lucas, John T., Mauz‐Körholz, Christine, McCarten, Kathleen M. , Pandit‐Taskar, Neeta, Steglich, Jonas , Stoevesandt, Dietrich, Voss, Stephan D. , Milgrom, Sarah A. , Lucas, John T. , Gowdy, Claire , Hoppe, Bradford S , Stoevesandt, Dietrich , Flerlage, Jamie E , Seelisch, Jennifer , Bradshaw, Tyler , Castellino, Sharon M. , Dieckmann, Karin, Kelly, Kara M. , Lucas, John T., Mauz‐Körholz, Christine , Pandit-Taskar, Neeta D. , Schöder, Heiko

Mayo Clinic

British Journal of Haematology | January 15, 2026 | Volume: 208 | Issue: 4 | Pages: 1185-1195

10.1111/bjh.70329 | PMID 41535222 Get It

Summary In adults with classic Hodgkin lymphoma (cHL), metabolic tumour volume (MTV) is valuable for risk stratification. This systematic review explored the role of volumetric parameters in children, adolescents and young adults (CAYA) with cHL. This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) method. Five databases were searched on 16 October 2024. Eligible studies were peer‐reviewed manuscripts, written in English, published since database inception that included patients ≤21 years of age with a diagnosis of cHL treated with chemotherapy ± radiotherapy with a baseline 18 F‐Fluorodeoxyglucose (F‐FDG) PET/CT scan for MTV quantification. The search strategy identified 3669 studies, of which 35 were eligible for inclusion. Fifteen studies (43%) evaluated a cohort exclusively ≤21 years of age. All eight studies that explored the association of baseline PET parameters with known risk factors identified a significant correlation. Nine of 12 papers (75%) demonstrated a statistically significant correlation with disease response to therapy on PET/CT. Fifteen of 20 papers (75%) demonstrated an independent statistically significant correlation with clinical outcomes. In the CAYAHL population, volumetric PET parameters are valuable for risk stratification despite heterogeneity in results. Future harmonization of the segmentation approach will facilitate incorporation of MTV into clinical practice.
Epilepsy disease classification: a community effort to enhance the Mondo Disease Ontology
Vasilevsky, Nicole, Gehrke, Sarah , Mullen, Kathleen , Barua, Subit , Braun, Ian , Brünger, Tobias , Ivaniuk, Alina, Korn, Daniel, Lal, Dennis , Marsh, Stephanie, O’Loughlin, Elaine, Olson, Daniel, Shwetar, Yousif, Vanessa, Vogel-Farley, Grabenstatter, Heidi L. , Haendel, Melissa, Mungall, Christopher, Toro, Sabrina, Vasilevsky, Nicole A , Korn, Daniel , Lal, Dennis , Haendel, Melissa , Mungall, Christopher J , Coughlin, Curtis R. , Ivaniuk, Alina , O'Loughlin, Elaine K. , Olson, Daniel , Shwetar, Yousif J. , Sofocleous, Christalena , Vogel‐Farley, Vanessa K. , Haendel, Melissa , Toro, Sabrina

Mayo Clinic

Database | January 14, 2026 | Volume: 2026 | Issue: No issue available | Pages: No page available

10.1093/database/baag004 | PMID 41697974 Get It

Abstract Motivation: Epilepsy is a diverse group of neurological disorders affecting over 50 million people worldwide. While common epilepsy types are well studied, rare epilepsies—often severe and genetically complex—pose significant challenges in diagnosis, research, and treatment. Accurate and interoperable etiology and disease classifications are critical for improving data sharing, supporting clinical decision-making, and advancing rare disease research. Results: To enhance the accuracy of epilepsy-related disease concept representation within the Mondo Disease Ontology (Mondo), we conducted a series of expert-driven workshops in collaboration with the team from the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). Specialists in epileptology, genetics, neurodevelopment, biomedical ontology, and patient community advocates systematically reviewed and revised the epilepsy hierarchy in Mondo, aligning it with the International League Against Epilepsy (ILAE) classification system. These updates include reclassification of epilepsy subtypes, including syndromes, age-related epilepsies, and developmental epileptic encephalopathies, resulting in a more granular, standardized, and clinically relevant structure. Mondo now offers an enhanced framework for integrating epilepsy data across resources, enabling improved interoperability and facilitating rare disease research and data curation, with continued efforts underway to further refine and expand this integration.
Prevalence of Clinically Symptomatic Chronic Respiratory Alkalosis (CSCRA) in Patients Seen for Vestibular Assessment
Kingsbury, Sarah , Kingsbury, Hailey, Pradhan, Gaurav N. , Cevette, Michael J. , Vanood, Nile, Breznak, Karen K., Stepánek, Jan , Kingsbury, Sarah E , Pradhan, Gaurav N , Stepánek, Jan

Mayo Clinic

Journal of Otorhinolaryngology, Hearing and Balance Medicine | January 14, 2026 | Volume: 7 | Issue: 1 | Pages: 6

10.3390/ohbm7010006 Get It

Background/Objectives: Dizziness is a symptom of many disorders across a wide range of etiologies. If dizzy patients are seen for vestibular evaluation with an audiologist and no vestibular reason for the patient’s dizziness is found, the medical referral pathway can become convoluted. This can leave patients feeling discouraged and unable to manage their symptoms. Clinically symptomatic chronic respiratory alkalosis (CSCRA) is an acid–base disorder that typically presents with dizziness but is unfamiliar to practitioners in vestibular and balance care settings. Methods: In a retrospective chart review deemed exempt by the Mayo Clinic Institutional Review Board, 74 patients at Mayo Clinic Arizona were included. All had consultations with both Audiology and Aerospace Medicine to assess their dizzy symptoms. Results: After completing vestibular testing, arterial blood gas (ABG) testing, and a functional test developed at Mayo Clinic Arizona called the Capnic Challenge test, 40% of patients were found to have CSCRA contributing to their dizzy symptoms. Many of these patients also had common comorbidities of CSCRA, like postural orthostatic tachycardia syndrome (POTS), migraines, and sleep apnea. Fewer than one-fourth of these patients had measurable vestibulopathies causing their dizziness. Half of the patients referred by the vestibular audiologist to Aerospace Medicine had a diagnosis of CSCRA. Conclusions: Assessment for CSCRA should be considered as a next step for patients presenting with dizziness without a vestibular component. Being aware of the prevalence of CSCRA and its comorbidities may help balance providers offer quality interprofessional referrals and improve patient quality of life.